Last reviewed · How we verify
Rifamycin-containing regimen
Rifamycin-containing regimen is a Rifamycin antibiotic Small molecule drug developed by National Taiwan University Hospital. It is currently FDA-approved for Tuberculosis (as part of combination therapy), Mycobacterial infections, Other bacterial infections (in combination regimens).
Rifamycins inhibit bacterial RNA polymerase, preventing transcription and blocking bacterial protein synthesis.
Rifamycins inhibit bacterial RNA polymerase, preventing transcription and blocking bacterial protein synthesis. Used for Tuberculosis (as part of combination therapy), Mycobacterial infections, Other bacterial infections (in combination regimens).
At a glance
| Generic name | Rifamycin-containing regimen |
|---|---|
| Sponsor | National Taiwan University Hospital |
| Drug class | Rifamycin antibiotic |
| Target | Bacterial RNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Rifamycins are a class of antibiotics that bind to the bacterial RNA polymerase enzyme and inhibit RNA synthesis by blocking the path of elongating RNA transcripts. This mechanism is highly selective for bacterial RNA polymerase and has minimal effect on eukaryotic enzymes. Rifamycin-containing regimens are typically used in combination with other antimicrobial agents to treat infections caused by susceptible bacteria, particularly Mycobacterium tuberculosis and other mycobacterial species.
Approved indications
- Tuberculosis (as part of combination therapy)
- Mycobacterial infections
- Other bacterial infections (in combination regimens)
Common side effects
- Hepatotoxicity
- Gastrointestinal disturbance
- Rash
- Drug interactions (enzyme induction)
- Orange discoloration of body fluids
Key clinical trials
- Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis (PHASE3)
- Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study (PHASE2)
- Short-Course Anti-tuberculosis Regimens for Mild Spinal Tuberculosis (PHASE2)
- Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis (PHASE2)
- Four Months Moxifloxacin Containing Daily Regimen Study Among New Pulmonary Tuberculosis Patients
- Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer (PHASE2)
- Assessing PA-824 for Tuberculosis (the APT Trial) (PHASE2)
- The Safety, Completion Rate and Prevention Effect by Rifamycin-containing Regimens for Latent Tuberculosis Infection in Patients With Kidney Transplantation: a Prospective Intervention Pilot Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rifamycin-containing regimen CI brief — competitive landscape report
- Rifamycin-containing regimen updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI
Frequently asked questions about Rifamycin-containing regimen
What is Rifamycin-containing regimen?
How does Rifamycin-containing regimen work?
What is Rifamycin-containing regimen used for?
Who makes Rifamycin-containing regimen?
What drug class is Rifamycin-containing regimen in?
What development phase is Rifamycin-containing regimen in?
What are the side effects of Rifamycin-containing regimen?
What does Rifamycin-containing regimen target?
Related
- Drug class: All Rifamycin antibiotic drugs
- Target: All drugs targeting Bacterial RNA polymerase
- Manufacturer: National Taiwan University Hospital — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Tuberculosis (as part of combination therapy)
- Indication: Drugs for Mycobacterial infections
- Indication: Drugs for Other bacterial infections (in combination regimens)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing